Jeroen Tonnaer joined Cristal Therapeutics in 2015 as Chief Business Officer. He is responsible for the Company’s business development, partnering and licensing activities.
Jeroen Tonnaer has over 30 years of experience in drug discovery and development, research strategy, business development and licensing.
He served in several leading positions at Organon and Schering-Plough, and was involved in business liaison roles for Schering-Plough in the public-private partnership Top Institute Pharma (TI Pharma). After Schering-Plough’s acquisition by Merck & Co, also known as Merck Sharpe & Dohme (MSD) outside North America, Jeroen headed Merck's European External Scientific Affairs team, and was instrumental in the identification and execution of several major licensing and partnering deals with companies such as Ablynx, AiCuris and Delphi Genetics.
Jeroen Tonnaer holds an MSc degree in biology, a PhD in Pharmacology and is a Certified Licensing Professional (CLP™).